Biotech companies report on drugs to treat head and neck, lung cancers

06/7/2004 | Reuters · Wall Street Journal, The

Genentech and ImClone reported success in developing a pair of drugs that treat head and neck cancer and lung cancer, respectively. Genentech said combining its Tarceva and Avastin can extend the survival rate of patients with lung cancer and ImClone said Erbitux, FDA-approved for treating colon cancer, can work with radiation to increase the median survival rate of patients with head and neck cancer.

View Full Article in:

Reuters · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX